Muscular Dystrophy during Osteoarthritic Disorder: A Novel Diagnostic Protocol Evidenced by Biochemical and Anatomical Parameters

Background: Muscular Dystrophy during Osteoarthritic Disorder (MD-OAD) is a group of disorders characterized by muscle wasting, weakness and degeneration along with potential loss of joint cartilage, bone hypertrophy, painful Joint effusion and restricted movement of joints. Creatine Kinase-Muscle (CK-MM) and AldolaseA (AldoA) are considered to be realistic biomarkers to detect the MD-OAD. The aim of the study was to evaluate the serum levels of CK-MM and AldoA and determine their correlation with risk factors such as muscle weakness, muscle degeneration, skeletal muscle damage resulting in deranged anatomical features developed in MD-OAD. Methods: Baseline data from 162 patients, aged 59.89±7.19 years, suffering with MD-OADs for 7.89±1.90 years and 153 participants, aged 58.96±8.63 years, without MD-OADs were collected in this crosssectional study. Separate analyses were performed for participants with and without MD-OAD symptoms confirming with electromyography, musculoskeletal ultrasound, muscle biopsy, CT-scan and MRI. Serum CK-MM and AldoA levels were estimated. All subjects, with and without MD-OADs, underwent standardized physical, radiographic, other related examinations and completed a questionnaire. Results: The levels of CK-MM and AldoA of experimental subjects, representing the risk factor of MD-OADs, were increased their mean±SD values 248.42±100.96 and 8.87±2.70 U/L respectively and abnormal anatomical features, pain syndromes and obesity were all exhibited highly significant differences (p<0.0001) when compared with the control subjects. Conclusion: It is firmly concluded that monitoring the levels of serum CK-MM and AldoA along with anatomical parameters features, pain free life-style and body weight, even at early progressive stage, may be effective diagnostic protocol for detecting MD-OAD.